Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mechanisms leading to T-cell activation in drug hypersensitivity

Mechanisms leading to T-cell activation in drug hypersensitivity Purpose of reviewDelayed-type or nonimmediate drug hypersensitivity reactions often involve the activation of drug-specific T cells. As such, the molecular initiating event is an interaction between HLA proteins, HLA-binding peptides and the drug. For many years, the formation of covalently modified drug protein adducts was assumed to be a prerequisite for T-cell activation. The purpose of this article is to review recent studies using human PBMC, T-cell lines and clones, which show that drugs are in fact loaded onto HLA molecules in different forms to activate T cells.Recent findingsWe now know that protein-reactive drugs such as β-lactam antibiotics activate T cells via direct noncovalent interactions with HLA or HLA-binding peptides, direct covalent modification of HLA-binding peptides and covalent binding of non-HLA associated proteins. Adducts formed inside and outside of the cells undergo protein processing to generate HLA-binding peptides that are assumed to contain the drug modification. Studies using synthetic stable (e.g. oxypurinol) and reactive (e.g. nitroso sulfamethoxazole) metabolites show that metabolites activate T cells via the same pathways. A variety of drugs with different structural features have also been shown to activate T cells though a direct HLA-binding interaction. Of note, abacavir behaves in an unexpected way, binding deep in the peptide binding cleft of one HLA, selectively activating CD8+ T cells.SummaryIn-vitro studies have revealed that a number of drug HLA-binding interactions lead to the activation of T cells. These can be categorized according to two hypotheses, namely hapten and pharmacological interactions. As we move forward with the development of diagnostic and predictive T-cell assays, it is critical to reach a consensus that direct drug HLA binding and the formation of drug protein adducts are important events for T-cell activation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy and Clinical Immunology Wolters Kluwer Health

Mechanisms leading to T-cell activation in drug hypersensitivity

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/mechanisms-leading-to-t-cell-activation-in-drug-hypersensitivity-y7Zz6BztFj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000458
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewDelayed-type or nonimmediate drug hypersensitivity reactions often involve the activation of drug-specific T cells. As such, the molecular initiating event is an interaction between HLA proteins, HLA-binding peptides and the drug. For many years, the formation of covalently modified drug protein adducts was assumed to be a prerequisite for T-cell activation. The purpose of this article is to review recent studies using human PBMC, T-cell lines and clones, which show that drugs are in fact loaded onto HLA molecules in different forms to activate T cells.Recent findingsWe now know that protein-reactive drugs such as β-lactam antibiotics activate T cells via direct noncovalent interactions with HLA or HLA-binding peptides, direct covalent modification of HLA-binding peptides and covalent binding of non-HLA associated proteins. Adducts formed inside and outside of the cells undergo protein processing to generate HLA-binding peptides that are assumed to contain the drug modification. Studies using synthetic stable (e.g. oxypurinol) and reactive (e.g. nitroso sulfamethoxazole) metabolites show that metabolites activate T cells via the same pathways. A variety of drugs with different structural features have also been shown to activate T cells though a direct HLA-binding interaction. Of note, abacavir behaves in an unexpected way, binding deep in the peptide binding cleft of one HLA, selectively activating CD8+ T cells.SummaryIn-vitro studies have revealed that a number of drug HLA-binding interactions lead to the activation of T cells. These can be categorized according to two hypotheses, namely hapten and pharmacological interactions. As we move forward with the development of diagnostic and predictive T-cell assays, it is critical to reach a consensus that direct drug HLA binding and the formation of drug protein adducts are important events for T-cell activation.

Journal

Current Opinion in Allergy and Clinical Immunology – Wolters Kluwer Health

Published: Aug 1, 2018

References

  • HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
  • Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury
  • Promiscuous T-cell responses to drugs and drug-haptens
  • HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin
  • Studies on the sensitization of animals with simple chemical compounds
  • Immunity to halothane metabolite-modified proteins in halothane hepatitis
  • A study of the prevalence of penicillin-specific IgG, IgM and IgE antibodies detected by ELISA and defined by hapten inhibition, in patients with suspected penicillin allergy and in healthy volunteers
  • Nonimmediate reactions to betalactams
  • Study of protein haptenation by amoxicillin through the use of a biotinylated antibiotic
  • Detection of antiisoniazid and anticytochrome P450 antibodies in patients with isoniazid-induced liver failure
  • Mass spectrometric characterization of circulating covalent protein adducts derived from epoxide metabolites of carbamazepine in patients
  • Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis
  • Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis
  • Amoxicillin and clavulanate form chemically and immunologically distinct multiple haptenic structures in patients
  • The role of IgE recognition in allergic reactions to amoxicillin and clavulanic acid
  • Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals
  • Definition of the nature and hapten threshold of the beta-lactam antigen required for T Cell activation in vitro and in patients
  • Identification of T-cell epitopes from benzylpenicillin conjugated to human serum albumin and implication in penicillin allergy
  • Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy
  • Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis
  • Stimulation of human T cells with sulfonamides and sulfonamide metabolites
  • HLA peptide length preferences control CD8+ T cell responses
  • Antigen processing and presentation: TAPping into ABC transporters
  • Antigen presentation by extracellular vesicles from professional antigen-presenting cells
  • Amoxicillin haptenates intracellular proteins that can be transported in exosomes to target cells
  • Immature, but not inactive: the tolerogenic function of immature dendritic cells
  • Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
  • Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to beta-lactams
  • Betalactam antibiotics affect human dendritic cells maturation through MAPK/NF-kB systems. Role in allergic reactions to drugs
  • HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes
  • T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity
  • Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B∗58:01
  • Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones
  • Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones
  • Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity
  • Immune self-reactivity triggered by drug-modified HLA-peptide repertoire
  • Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire
  • Structural elements recognized by abacavir-induced T cells
  • HLA-B∗1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome
  • Avidity determines T-cell reactivity in abacavir hypersensitivity
  • Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome
  • Early immune events in the induction of allergic contact dermatitis
  • Abacavir induced T cell reactivity from drug naive individuals shares features of allo-immune responses